Logo

Pfizer to Discontinue P-III (REALM-DCM) Trial of PF-07265803 for the Treatment of LMNA-Related Dilated Cardiomyopathy

Share this
Pfizer to Discontinue P-III (REALM-DCM) Trial of PF-07265803 for the Treatment of LMNA-Related Dilated Cardiomyopathy

Pfizer to Discontinue P-III (REALM-DCM) Trial of PF-07265803 for the Treatment of LMNA-Related Dilated Cardiomyopathy

Shots:

  • The company will stop the P-III (REALM-DCM) trial to evaluate the efficacy and safety of PF-07265803 (p38α MAPK antagonist) in patients with symptomatic DCM due to a mutation of the gene encoding LMNA
  • The decision was based on the results of interim futility analysis which indicated that the P-III trial failed to meet its 1EPs. Additionally, PF-07265803’s development will be discontinued, based on the P-III trial results
  • Additionally, enrolled patients will stop receiving study treatment and complete any required follow-up assessments. The company is actively working with regulatory authorities globally, investigators, and community groups regarding the discontinuation

Ref: Pfizer | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions